Key takeaways<\/p>\n
In the 2026 Algerian guideline, stage III TNBC is managed with neoadjuvant chemotherapy + pembrolizumab.
\n Pathological response after neoadjuvant treatment can influence subsequent therapy.
\n BRCA1\/2 testing can identify patients eligible for olaparib in the appropriate high-risk setting.
\n The RCP has an increasingly important role in integrating pathology, biology, response and treatment access.<\/p>\n
For years, triple-negative breast cancer (TNBC) was largely synonymous with chemotherapy. In Algeria, as elsewhere, this remains an important part of treatment\u2014but the therapeutic approach is changing.<\/p>\n
The 2026 Algerian Guides Th\u00e9rapeutiques en Oncologie M\u00e9dicale now incorporate immunotherapy and germline BRCA-directed treatment into the management of high-risk TNBC. For stage III disease, the recommended standard is neoadjuvant chemotherapy combined with pembrolizumab. The subsequent strategy is influenced by the pathological response obtained at surgery.
This represents an important shift in clinical practice.<\/p>\n
The response to neoadjuvant treatment now matters<\/p>\n
Neoadjuvant treatment is no longer simply a way to reduce tumour size before surgery. The pathological response provides information that can influence what happens next. BRCA testing can change the pathway<\/p>\n TNBC should also prompt consideration of germline BRCA1\/2 testing, particularly in patients in whom the result could influence treatment. It increasingly becomes: What does this mean for practice in Algeria?<\/p>\n The challenge is not only adopting new recommendations. It is making sure that the diagnostic pathway can support them.
According to the 2026 Algerian guidelines<\/a>, patients achieving a pathological complete response (pCR) after neoadjuvant chemo-immunotherapy do not receive additional systemic adjuvant treatment in this specific pathway.
This makes the post-operative pathology report increasingly important\u2014not only for prognosis, but for treatment planning.<\/p>\n
The Algerian 2026 guideline specifically includes one year of adjuvant olaparib for patients with a BRCA1\/2 mutation in the relevant high-risk setting.
This means that the question in the RCP is no longer simply:
\u201cWhich chemotherapy should we give?\u201d<\/p>\n
\u201cWhat is the tumour biology, what was the response to neoadjuvant therapy, and is there an actionable germline alteration?\u201d<\/p>\n
For an Algerian patient with TNBC, treatment planning may now require coordinated access to pathology, appropriate biomarker assessment, genetic testing when indicated, surgery, radiotherapy and systemic therapy.
The RCP therefore becomes central: treatment decisions need to integrate stage, pathological response, BRCA status, comorbidities and access to the recommended treatments.
The evolution is significant, but implementation matters.<\/p>\n